ZTS
Zoetis Inc. NYSE Listed Feb 1, 2013$78.71
+1.88%
vs $77.26
Mkt Cap $33.0B
52w Low $72.38
7.1% of range
52w High $161.77
50d MA $94.33
200d MA $120.72
P/E (TTM)
12.8x
EV/EBITDA
10.1x
P/B
10.5x
Debt/Equity
2.9x
ROE
80.2%
P/FCF
15.3x
RSI (14)
53.20
ATR (14)
$2.50
Beta
0.97
50d MA
$94.33
200d MA
$120.72
Avg Volume
9.0M
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
10 Sylvan Way · Parsippany, NJ 07054 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | TNS | 1.60 | 1.53 | -4.4% | 87.31 | +0.0% | -5.1% | -7.4% | +0.4% | -3.4% | +1.5% | — |
| Feb 12, 2026 | TNS | 1.40 | 1.48 | +5.7% | 125.64 | +0.8% | +0.8% | -0.9% | +2.8% | -1.4% | +1.2% | — |
| Nov 4, 2025 | TNS | 1.62 | 1.70 | +4.9% | 124.46 | -0.2% | -3.2% | -0.8% | +0.6% | -0.4% | +0.3% | — |
| Aug 5, 2025 | TNS | 1.62 | 1.76 | +8.6% | 146.12 | +0.1% | +0.3% | +1.2% | -0.6% | +1.1% | +0.5% | — |
| May 6, 2025 | TNS | 1.41 | 1.48 | +5.0% | 149.87 | +1.2% | +4.1% | +3.7% | -1.5% | +1.7% | -0.9% | — |
| Feb 13, 2025 | TNS | 1.37 | 1.40 | +2.2% | 164.93 | -0.6% | -4.5% | -0.7% | +0.1% | +0.5% | +1.9% | — |
| Nov 4, 2024 | TNS | 1.46 | 1.58 | +8.2% | 175.18 | -0.4% | +0.1% | -2.8% | +2.3% | +1.5% | -0.4% | — |
| Aug 6, 2024 | TNS | 1.49 | 1.56 | +4.7% | 185.29 | +0.4% | -0.3% | +1.9% | -1.6% | -0.8% | +2.5% | — |
| May 2, 2024 | TNS | 1.34 | 1.38 | +3.0% | 167.23 | +1.9% | -0.1% | -0.7% | +1.5% | -2.1% | +1.9% | — |
| Feb 13, 2024 | TNS | 1.32 | 1.24 | -6.1% | 183.49 | +0.9% | +0.3% | +3.0% | -0.7% | -1.0% | +1.0% | — |
| Nov 2, 2023 | TNS | 1.36 | 1.36 | +0.0% | 160.91 | +2.1% | +0.8% | +0.6% | +2.4% | +2.2% | -0.1% | — |
| Aug 8, 2023 | TNS | 1.32 | 1.41 | +6.8% | 189.30 | +0.3% | +0.0% | -0.1% | +0.9% | -0.6% | -0.3% | — |
| May 4, 2023 | AMC | 1.26 | 1.31 | +4.0% | 178.47 | +0.9% | +4.3% | -0.7% | -0.3% | +0.4% | -0.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 27 | Argus | Downgrade | Buy → Hold | — | $80.23 | $80.02 | -0.3% | -0.9% | -1.5% | -0.7% | -0.2% | -1.5% |
| Apr 28 | UBS | Maintains | Neutral → Neutral | — | $117.87 | $117.23 | -0.5% | -1.0% | -2.4% | +1.0% | -0.7% | -1.3% |
| Feb 13 | BofA Securities | Maintains | Neutral → Neutral | — | $125.64 | $126.67 | +0.8% | +0.8% | -0.9% | +2.8% | -1.4% | +1.2% |
| Jan 22 | Piper Sandler | Downgrade | Overweight → Neutral | — | $125.08 | $124.27 | -0.6% | -0.5% | -0.3% | -0.1% | +0.8% | -2.4% |
| Dec 3 | BTIG | Maintains | Buy → Buy | — | $124.44 | $125.28 | +0.7% | -1.5% | -1.8% | -1.5% | -0.4% | -2.0% |
| Nov 18 | Stifel | Maintains | Hold → Hold | — | $118.80 | $118.43 | -0.3% | -0.6% | -0.9% | -1.0% | +5.3% | +0.7% |
| Nov 12 | BTIG | Maintains | Buy → Buy | — | $120.12 | $120.18 | +0.1% | +0.9% | -0.1% | -0.3% | -1.7% | -0.6% |
| Nov 10 | Morgan Stanley | Maintains | Overweight → Overweight | — | $120.24 | $120.43 | +0.2% | -0.4% | +0.3% | +0.9% | -0.1% | -0.3% |
| Nov 5 | UBS | Maintains | Neutral → Neutral | — | $124.46 | $124.20 | -0.2% | -3.2% | -0.8% | +0.6% | -0.4% | +0.3% |
| Nov 5 | JP Morgan | Maintains | Overweight → Overweight | — | $124.46 | $124.20 | -0.2% | -3.2% | -0.8% | +0.6% | -0.4% | +0.3% |
| Oct 20 | UBS | Maintains | Neutral → Neutral | — | $144.06 | $143.87 | -0.1% | +0.7% | +0.7% | +0.7% | -0.5% | -0.3% |
| Sep 9 | Argus | Maintains | Buy → Buy | — | $151.75 | $151.41 | -0.2% | -1.3% | -0.2% | +0.8% | -1.6% | -1.3% |
| Aug 11 | Piper Sandler | Maintains | Overweight → Overweight | — | $147.35 | $147.67 | +0.2% | +1.1% | +0.5% | +1.8% | +0.4% | +0.7% |
| Jul 17 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $151.54 | $150.00 | -1.0% | -1.0% | -1.0% | -0.8% | +2.6% | +1.5% |
| Jun 18 | Stifel | Downgrade | Buy → Hold | — | $161.67 | $157.09 | -2.8% | -4.1% | +1.4% | +0.1% | +0.3% | -0.3% |
| May 12 | Piper Sandler | Maintains | Overweight → Overweight | — | $159.27 | $161.03 | +1.1% | +1.7% | -0.9% | -3.4% | +3.5% | +1.7% |
| May 7 | UBS | Maintains | Neutral → Neutral | — | $149.87 | $151.68 | +1.2% | +4.1% | +3.7% | -1.5% | +1.7% | -0.9% |
| Apr 14 | Stifel | Maintains | Buy → Buy | — | $149.44 | $151.46 | +1.4% | +0.9% | -1.1% | -1.6% | +1.3% | -1.2% |
| Feb 27 | Piper Sandler | Maintains | Overweight → Overweight | — | $164.99 | $164.60 | -0.2% | -0.0% | +1.4% | +2.0% | -0.4% | -1.7% |
| Feb 14 | Morgan Stanley | Maintains | Overweight → Overweight | — | $164.93 | $163.98 | -0.6% | -4.5% | -0.7% | +0.1% | +0.5% | +1.9% |
| Feb 14 | Barclays | Maintains | Overweight → Overweight | — | $164.93 | $163.98 | -0.6% | -4.5% | -0.7% | +0.1% | +0.5% | +1.9% |
| Feb 10 | Piper Sandler | Maintains | Overweight → Overweight | — | $171.43 | $171.43 | +0.0% | +0.3% | +1.4% | -0.2% | -5.1% | -4.5% |
| Jan 29 | Morgan Stanley | Maintains | Overweight → Overweight | — | $170.42 | $169.70 | -0.4% | -0.1% | +1.5% | -1.0% | +0.6% | +0.2% |
| Jan 7 | Stifel | Maintains | Buy → Buy | — | $165.90 | $163.20 | -1.6% | -1.5% | +0.9% | -1.0% | +1.8% | -1.1% |
| Oct 11 | JP Morgan | Maintains | Overweight → Overweight | — | $190.28 | $190.21 | -0.0% | -0.1% | +1.4% | -0.1% | +1.1% | -1.8% |
| Sep 18 | Stifel | Maintains | Buy → Buy | — | $195.71 | $196.80 | +0.6% | +0.4% | -1.6% | -0.3% | +0.5% | +0.1% |
| Aug 27 | Stifel | Maintains | Buy → Buy | — | $181.56 | $181.98 | +0.2% | +0.3% | +0.4% | -0.0% | +0.3% | +0.0% |
| Aug 14 | Piper Sandler | Maintains | Overweight → Overweight | — | $188.38 | $188.05 | -0.2% | -2.7% | +0.4% | -0.2% | +0.4% | -0.5% |
| Aug 12 | BTIG | Maintains | Buy → Buy | — | $185.25 | $184.86 | -0.2% | -0.8% | +2.5% | -2.7% | +0.4% | -0.2% |
| Aug 7 | Barclays | Maintains | Overweight → Overweight | — | $185.29 | $186.00 | +0.4% | -0.3% | +1.9% | -1.6% | -0.8% | +2.5% |
| Aug 5 | Stifel | Maintains | Buy → Buy | — | $180.59 | $176.18 | -2.4% | -3.2% | +6.0% | -0.3% | +1.9% | -1.6% |
| May 8 | HSBC | Maintains | Buy → Buy | — | $168.45 | $167.08 | -0.8% | -2.1% | +1.9% | +0.5% | -0.7% | +0.6% |
| May 6 | Goldman Sachs | Maintains | Buy → Buy | — | $167.07 | $167.35 | +0.2% | -0.7% | +1.5% | -2.1% | +1.9% | +0.5% |
| Apr 30 | Stifel | Maintains | Buy → Buy | — | $159.70 | $159.64 | -0.0% | -0.3% | -0.5% | +5.5% | -0.1% | -0.7% |
| Apr 23 | Barclays | Maintains | Overweight → Overweight | — | $145.54 | $146.25 | +0.5% | +2.8% | +0.9% | +1.6% | +3.3% | +0.8% |
| Apr 16 | Piper Sandler | Maintains | Overweight → Overweight | — | $149.77 | $150.20 | +0.3% | +2.2% | -0.7% | +0.8% | -4.3% | -0.7% |
| Apr 2 | Stifel | Maintains | Buy → Buy | — | $167.02 | $165.67 | -0.8% | -1.2% | -1.2% | +1.6% | +0.2% | -0.1% |
| Feb 20 | Piper Sandler | Maintains | Overweight → Overweight | — | $188.39 | $187.30 | -0.6% | -1.0% | +1.0% | +4.4% | +0.3% | -0.1% |
| Feb 14 | Barclays | Maintains | Overweight → Overweight | — | $183.49 | $185.19 | +0.9% | +0.3% | +3.0% | -0.7% | -1.0% | +1.0% |
| Jan 17 | Goldman Sachs | Maintains | Buy → Buy | — | $192.99 | $191.99 | -0.5% | -1.1% | -0.2% | -1.1% | +1.5% | -1.6% |
| Nov 6 | Piper Sandler | Maintains | Overweight → Overweight | — | $162.23 | $170.28 | +5.0% | +0.6% | +2.4% | +2.2% | -0.1% | -0.8% |
| Oct 30 | Stifel | Maintains | Buy → Buy | — | $156.03 | $157.13 | +0.7% | +0.6% | +0.0% | -3.5% | +6.3% | +0.8% |
| Sep 12 | Stifel | Maintains | Buy → Buy | — | $186.07 | $185.23 | -0.5% | +0.9% | -3.0% | +0.4% | -1.4% | -0.3% |
| Aug 28 | Stifel | Maintains | Buy → Buy | — | $182.82 | $184.51 | +0.9% | +2.3% | +3.1% | -0.0% | -1.1% | +1.1% |
| Aug 14 | Piper Sandler | Maintains | Overweight → Overweight | — | $190.83 | $190.21 | -0.3% | -0.6% | -0.3% | -1.5% | -1.9% | -0.7% |
| Aug 10 | Goldman Sachs | Maintains | Buy → Buy | — | $189.35 | $190.00 | +0.3% | -0.1% | +0.9% | -0.6% | -0.3% | -1.5% |
| Jun 14 | Atlantic Equities | Maintains | Overweight → Overweight | — | $166.01 | $167.08 | +0.6% | -0.2% | +3.5% | -0.4% | -1.1% | +0.6% |
| May 26 | Atlantic Equities | Maintains | Overweight → Overweight | — | $165.24 | $165.66 | +0.3% | -0.3% | -2.3% | +1.3% | +1.8% | +3.5% |
| May 8 | Piper Sandler | Maintains | Overweight → Overweight | — | $186.23 | $186.31 | +0.0% | -0.7% | -0.3% | +0.4% | -0.0% | -0.8% |
| Feb 21 | Barclays | Maintains | Overweight → Overweight | — | $172.03 | $171.53 | -0.3% | -1.3% | -2.0% | +1.8% | -1.9% | -0.5% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 13, 2026 | Bisaro PaulDir | — | Buy | 2,000 | $75.88 | $152K | 27,862 | +1.53% | +1.00% |
| May 13, 2026 | DAMELIO FRANK ADir | — | Buy | 6,650 | $75.39 | $501K | 21,458 | +1.53% | +1.00% |
| May 11, 2026 | MCCALLISTER MICHAEL BDir | — | Buy | 3,000 | $77.76 | $233K | 24,524 | -3.38% | +1.54% |
8-K · 5.02
!!! Very High
Zoetis Inc. -- 8-K 5.02: Executive Change
May 22
8-K
ZOETIS INC. -- 8-K Filing
Zoetis reported Q4 and full-year 2025 results and issued 2026 guidance, providing investors with updated financial performance metrics and forward-looking expectations for the animal health company.
Feb 12
8-K · 7.01
! Medium
ZOETIS INC. -- 8-K 7.01: Regulation FD Disclosure
Zoetis declared a $0.53 per share dividend payable June 2, 2026, to shareholders of record April 20, 2026, providing steady income returns to investors.
Feb 5
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 30,931,012 | $3.9B | Reduced | Dec 2025 |
| 2 | Vanguard Capital Management Llc | 26,072,846 | $3.1B | New | Mar 2026 |
| 3 | Vanguard Portfolio Management Llc | 23,967,400 | $2.8B | New | Mar 2026 |
| 4 | State Farm Mutual Automobile Insurance Co | 15,892,903 | $1.9B | — | Mar 2026 |
| 5 | Nordea Investment Management Ab | 5,865,111 | $680M | Added | Mar 2026 |
| 6 | Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main | 3,390,804 | $662M | — | Sep 2024 |
| 7 | Northern Trust Corp | 5,546,057 | $656M | Reduced | Mar 2026 |
| 8 | Wells Fargo & Company/mn | 5,491,173 | $649M | New | Mar 2026 |
| 9 | Bank Of America Corp /de/ | 4,831,652 | $571M | Reduced | Mar 2026 |
| 10 | Mitsubishi Ufj Asset Management Co., Ltd. | 4,244,351 | $502M | — | Mar 2026 |
| 11 | Polen Capital Management Llc | 4,223,076 | $499M | Reduced | Mar 2026 |
| 12 | Bank Of New York Mellon Corp | 3,899,720 | $461M | Reduced | Mar 2026 |
| 13 | Janus Henderson Group Plc | 3,701,747 | $438M | New | Mar 2026 |
| 14 | Invesco Ltd. | 3,540,968 | $419M | Added | Mar 2026 |
| 15 | Diamond Hill Capital Management Inc | 3,158,638 | $397M | Added | Dec 2025 |
| 16 | Jpmorgan Chase & Co | 3,387,174 | $394M | Added | Mar 2026 |
| 17 | Amundi | 3,166,361 | $374M | New | Mar 2026 |
| 18 | Raymond James Financial Inc | 3,166,615 | $374M | Added | Mar 2026 |
| 19 | Swedbank Ab | 3,004,200 | $355M | Added | Mar 2026 |
| 20 | Nuveen, Llc | 2,965,717 | $351M | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$33.00B
Enterprise Value
$41.22B
P/E (TTM)
12.83x
Forward P/E
11.20x
PEG Ratio
2.04x
P/B
10.48x
P/S
3.69x
P/FCF
15.30x
EV/EBITDA
10.13x
Shares Out
443.8M
Financials (TTM)
Revenue
$9.47B
Net Income
$2.67B
EBITDA
$4.07B
Free Cash Flow
$2.28B
Op Cash Flow
$2.90B
EPS Basic
$6.03
EPS Diluted
$6.02
EPS Forward
$7.03
Gross Margin
70.5%
Op Margin
38.0%
Net Margin
28.2%
Balance Sheet
Total Assets
$15.47B
Total Liab.
$12.14B
Total Equity
$3.33B
Cash
$2.31B
LT Debt
$9.24B
Book Value/Sh
$7.51
Debt/Equity
2.85x
Current Ratio
3.03
Quick Ratio
1.94
Returns & Growth
ROE
80.2%
ROA
17.3%
ROIC
21.5%
Rev Growth YoY
+2.3%
EPS Growth YoY
+10.2%
Price Returns
2W
+2.9%
1M
-32.4%
3M
-40.7%
6M
-39.4%
12M
-53.9%
Technicals
52W High
$161.77
52W Low
$72.38
50d MA
$94.33
200d MA
$120.72
RSI (14)
53.20
ATR (14)
$2.50
Beta
0.97
Avg Volume
9.0M
Dividends
Div Rate
$2.00
Div Yield
1.8%
Frequency
4
Ex-Div Date
Apr 20, 2026
Analyst Price Targets
Consensus
$143.00
High
$160.00
Low
$130.00
Median
$140.00
Data updated apr 27, 2026 11:51am
· Source: financialmodelingprep.com